Daphne Quimi - Net Worth and Insider Trading

Daphne Quimi Net Worth

The estimated net worth of Daphne Quimi is at least $4 Million dollars as of 2024-11-13. Daphne Quimi is the CFO of Amicus Therapeutics Inc and owns about 398,532 shares of Amicus Therapeutics Inc (FOLD) stock worth over $4 Million. Daphne Quimi is the Director of Amylyx Pharmaceuticals Inc and owns about 5,000 shares of Amylyx Pharmaceuticals Inc (AMLX) stock worth over $31,175. Daphne Quimi is also the Director of Century Therapeutics Inc and owns about 5,000 shares of Century Therapeutics Inc (IPSC) stock worth over $7,050. Details can be seen in Daphne Quimi's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daphne Quimi has not made any transactions after 2024-09-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Daphne Quimi

To

Daphne Quimi Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daphne Quimi owns 3 companies in total, including Amicus Therapeutics Inc (FOLD) , Amylyx Pharmaceuticals Inc (AMLX) , and Century Therapeutics Inc (IPSC) .

Click here to see the complete history of Daphne Quimi’s form 4 insider trades.

Insider Ownership Summary of Daphne Quimi

Ticker Comapny Transaction Date Type of Owner
FOLD Amicus Therapeutics Inc 2023-01-18 Chief Financial Officer
AMLX Amylyx Pharmaceuticals Inc 2024-05-15 director
IPSC Century Therapeutics Inc 2024-09-12 director

Daphne Quimi Latest Holdings Summary

Daphne Quimi currently owns a total of 3 stocks. Among these stocks, Daphne Quimi owns 398,532 shares of Amicus Therapeutics Inc (FOLD) as of January 18, 2023, with a value of $4 Million and a weighting of 99.09%. Daphne Quimi owns 5,000 shares of Amylyx Pharmaceuticals Inc (AMLX) as of May 15, 2024, with a value of $31,175 and a weighting of 0.74%. Daphne Quimi also owns 5,000 shares of Century Therapeutics Inc (IPSC) as of September 12, 2024, with a value of $7,050 and a weighting of 0.17%.

Latest Holdings of Daphne Quimi

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
FOLD Amicus Therapeutics Inc 2023-01-18 398,532 10.49 4,180,601
AMLX Amylyx Pharmaceuticals Inc 2024-05-15 5,000 6.24 31,175
IPSC Century Therapeutics Inc 2024-09-12 5,000 1.41 7,050

Holding Weightings of Daphne Quimi


Daphne Quimi Form 4 Trading Tracker

According to the SEC Form 4 filings, Daphne Quimi has made a total of 8 transactions in Amicus Therapeutics Inc (FOLD) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Amicus Therapeutics Inc is the sale of 11,923 shares on January 18, 2023, which brought Daphne Quimi around $152,495.

According to the SEC Form 4 filings, Daphne Quimi has made a total of 1 transactions in Amylyx Pharmaceuticals Inc (AMLX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Amylyx Pharmaceuticals Inc is the acquisition of 5,000 shares on May 15, 2024, which cost Daphne Quimi around $9,450.

According to the SEC Form 4 filings, Daphne Quimi has made a total of 1 transactions in Century Therapeutics Inc (IPSC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Century Therapeutics Inc is the acquisition of 5,000 shares on September 12, 2024, which cost Daphne Quimi around $7,650.

Insider Trading History of Daphne Quimi

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daphne Quimi Trading Performance

GuruFocus tracks the stock performance after each of Daphne Quimi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daphne Quimi is 18.68%. GuruFocus also compares Daphne Quimi's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daphne Quimi within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Daphne Quimi's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Daphne Quimi

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.62 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -7.75 LIMIT LIMIT LIMIT LIMIT LIMIT

Daphne Quimi Ownership Network

Ownership Network List of Daphne Quimi

No Data

Ownership Network Relation of Daphne Quimi

Insider Network Chart

Daphne Quimi Owned Company Details

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

Daphne Quimi is the Chief Financial Officer of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, Daphne Quimi made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 232,762 shares made by Bradley L Campbell , a net sale of 333,235 shares made by John F Crowley , and a net sale of 95,000 shares made by Ellen Rosenberg .

In summary, during the past 3 months, insiders sold 30,401 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 30,401 shares. During the past 18 months, 803,781 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 803,781 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Amicus Therapeutics Inc Insider Transactions

No Available Data

Daphne Quimi Mailing Address

Above is the net worth, insider trading, and ownership report for Daphne Quimi. You might contact Daphne Quimi via mailing address: C/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury Nj 08512.